Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for...
- Research study presented at the 2024 ASCO Quality Care Symposium uses Novellia's AI-enabled technology and personal health record platform to...
Scalable and adaptable, TETRIS captures the diversity of protein interactions on site to inform accurate cancer diagnoses, enabling the personalisation...
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by...
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary...
WASHINGTON & OXFORD, England--(BUSINESS WIRE)--#Healthcare--Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated...
BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is pleased...
STOCKHOLM, Sept. 27, 2024 /PRNewswire/ -- RaySearch's founder and CEO, Johan Löf, has sold 150,000 Class B shares in RaySearch...
Pelvic health startup Hyivy Health poised to offer better solutions to the 300M patients with pelvic floor dysfunction causing chronic...
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a...
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly...
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM,...
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA,...
Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025TEL AVIV, Israel, Sept. 27, 2024 (GLOBE NEWSWIRE) --...
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor...
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark...
New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute...
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for...
Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...